Severely compromised supply of patch test allergens in Europe hampers adequate diagnosis of occupational and non-occupational contact allergy. A European Society of Contact Dermatitis (ESCD), European Academy of Allergy and Clinical Immunology (EAACI), European Academy of Dermatology and Venereology (EADV) task forces 'Contact Dermatitis' and 'Occupational Skin Disease' position paper.
European Pharmacopoeia
Type IV allergy
allergen provocation test
marketing authorisation
patch test
regulatory framework
skin test allergens
Journal
Contact dermatitis
ISSN: 1600-0536
Titre abrégé: Contact Dermatitis
Pays: England
ID NLM: 7604950
Informations de publication
Date de publication:
29 May 2024
29 May 2024
Historique:
revised:
17
04
2024
received:
01
03
2024
accepted:
29
04
2024
medline:
30
5
2024
pubmed:
30
5
2024
entrez:
30
5
2024
Statut:
aheadofprint
Résumé
Patch testing is the only clinically applicable diagnostic method for Type IV allergy. The availability of Type IV patch test (PT) allergens in Europe, however, is currently scarce. This severely compromises adequate diagnostics of contact allergy, leading to serious consequences for the affected patients. Against this background, the European Society of Contact Dermatitis (ESCD) has created a task force (TF) (i) to explore the current availability of PT substances in different member states, (ii) to highlight some of the unique characteristics of Type IV vs. other allergens and (iii) to suggest ways forward to promote and ensure availability of high-quality patch testing substances for the diagnosis of Type IV allergies throughout Europe. The suggestions of the TF on how to improve the availability of PT allergens are supported by the ESCD, the European Academy of Allergy and Clinical Immunology, and the European Academy of Dermatology and Venereology and intend to provide potential means to resolve the present medical crisis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.
Références
Gell PGH, Coombs RRA. The classification of allergic reactions underlying disease. In: Coombs R, Gell P, eds. Clinical Aspects of Immunology. Blackwell Science; 1963:317‐337.
Diepgen TL, Ofenloch RF, Bruze M, et al. Prevalence of contact allergy in the general population in different European regions. Br J Dermatol. 2016;174(2):319‐329. doi:10.1111/bjd.14167
Thyssen JP, Maibach HI. Drug‐elicited systemic allergic (contact) dermatitis—update and possible pathomechanisms. Contact Dermatitis. 2008;59(4):195‐202. doi:10.1111/j.1600‐0536.2008.01367.x
Aquino M, Rosner G. Systemic contact dermatitis. Clin Rev Allergy Immunol. 2019;56(1):9‐18. doi:10.1007/s12016‐018‐8686‐z
Johansen JD, Aalto‐Korte K, Agner T, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing—recommendations on best practice. Contact Dermatitis. 2015;73(4):195‐221. doi:10.1111/cod.12432
Council Directive. 89/342/EEC of 3 May 1989 extending the scope of Directives 65/65/EEC and 75/319/EEC and laying down additional provisions for immunological medicinal products consisting of vaccines, toxins or serums and allergens. OJ. 1989;142:14‐15.
Directive 2001/83/EC of the European Parliament and of the council of 6 November 2001 on the community code relating to medicinal products for human use. OJ. 2001;311:67‐128.
European Medicines Agency. Concept paper on a guideline for allergen products development in moderate to low‐sized study populations (EMA/CHMP/251023/2018). Accessed August 25, 2023. https://www.ema.europa.eu/en/concept-paper-guideline-allergen-products-development-moderate-low-sized-study-populations
Co‐ordination Group for Mutual Recognition and Decentralised Procedures—Human (CMDh). Recommendations on common regulatory approaches for allergen products (CMDh/399/2019). Accessed August 25, 2023. https://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/procedural_guidance/01_General_Info/CMDh_399_2019_clean_Rev0_2020_07.pdf
Saetterstrøm B, Olsen J, Johansen JD. Cost‐of‐illness of patients with contact dermatitis in Denmark. Contact Dermatitis. 2014;71(3):154‐161. doi:10.1111/cod.12231
Spiewak R. Immunotherapy of allergic contact dermatitis. Immunotherapy. 2011;3(8):979‐996. doi:10.2217/imt.11.89
de Groot AC. Patch Testing. Test Concentrations for 5200 Chemicals. Acdegroot Publishing; 2022.
Johansen JD, Bonefeld CM, Schwensen JFB, Thyssen JP, Uter W. Novel insights into contact dermatitis. J Allergy Clin Immunol. 2022;149(4):1162‐1171. doi:10.1016/j.jaci.2022.02.002
Johansen JD, Werfel T. Highlights in allergic contact dermatitis 2018/2019. Curr Opin Allergy Clin Immunol. 2019;19(4):334‐340. doi:10.1097/ACI.0000000000000552
Herman A, Uter W, Rustemeyer T, et al. Position statement: the need for EU legislation to require disclosure and labelling of the composition of medical devices. J Eur Acad Dermatol Venereol. 2021;35(7):1444‐1448. doi:10.1111/jdv.17238
Mowitz M, Herman A, Baeck M, et al. N, N‐dimethylacrylamide—a new sensitizer in the FreeStyle Libre glucose sensor. Contact Dermatitis. 2019;81(1):27‐31. doi:10.1111/cod.13243
Herman A, Aerts O, Baeck M, et al. Allergic contact dermatitis caused by isobornyl acrylate in Freestyle® Libre, a newly introduced glucose sensor. Contact Dermatitis. 2017;77(6):367‐373. doi:10.1111/cod.12866
Ring J. Occupational skin disease—a major health problem in Europe. J Eur Acad Dermatol Venereol. 2017;31(6):919‐920. doi:10.1111/jdv.14307
Document 52021DC0323. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions EU strategic framework on health and safety at work 2021‐2027 Occupational safety and health in a changing world of work COM/2021/323 final. https://eur‐lex.europa.eu/legal‐content/EN/TXT/?uri=CELEX%3A52021DC0323&qid=1626089672913#PP1Contents
Goossens A, Morren M‐A. Contact allergy in children. In: Johansen JD, Mahler V, Lepoittevin J‐P, Frosch PJ, eds. Contact Dermatitis. Springer International Publishing; 2019:1‐24.
Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555‐562. doi:10.1111/bjd.12125
European Medicines Agency. ICH M4Q Common technical document for the registration of pharmaceuticals for human use—Quality—Scientific guideline. Accessed October 11, 2023. https://www.ema.europa.eu/en/ich‐m‐4‐q‐common‐technical‐document‐registration‐pharmaceuticals‐human‐use‐quality‐scientific
Jordan D. An overview of the common technical document (CTD) regulatory dossier. Medical Writing. 2014;23:101‐105. doi:10.1179/2047480614Z.000000000207
Bonertz A, Mahler V, Vieths S. New guidance on the regulation of allergen products: key aspects and outcomes. Curr Opin Allergy Clin Immunol. 2020;20(6):624‐630. doi:10.1097/aci.0000000000000687
European Medicines Agency. Guideline on the Clinical evaluation of diagnosticagent (CPMP/EWP/1119/98/Rev. 1). Accessed August 28, 2023. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-evaluation-diagnostic-agents_en.pdf
Regulation (EU). No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (Text with EEA relevance). OJ. 2014;158:1‐76.
SmartPractice Position on Allergen Resitrction. Accessed August 25, 2023. smartpracticeeurope.com/spegerman/pdfs/ESCD_Position_on_Allergen_Licensing_2022.pdf?utm_source=Redirect&utm_medium=Presentation
Klimek L, Hoffmann HJ, Kalpaklioglu AF, et al. In‐vivo diagnostic test allergens in Europe: a call to action and proposal for recovery plan—an EAACI position paper. Allergy. 2020;75(9):2161‐2169. doi:10.1111/all.14329
Geier J, Uter W, Lessmann H, Schnuch A. The positivity ratio—another parameter to assess the diagnostic quality of a patch test preparation. Contact Dermatitis. 2003;48(5):280‐282. doi:10.1034/j.1600‐0536.2003.00033.x
Brasch J, Henseler T. The reaction index: a parameter to assess the quality of patch test preparations. Contact Dermatitis. 1992;27(3):203‐204. doi:10.1111/j.1600‐0536.1992.tb05267.x